MORGAN STANLEY PLC/CALL/AMGEN/280/0.1/20.12.24 | Market Closed - Börse Stuttgart 11:59:28 28/06/2024 pm IST | ||
| 4.43 EUR | +0.91% |
|
| Current month | +10.75% | ||
| 1 month | +8.58% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 4.43 | +0.91% |
| 27/24/27 | 4.39 | -6.40% |
| 26/24/26 | 4.69 | -5.06% |
| 25/24/25 | 4.94 | +4.66% |
| 24/24/24 | 4.72 | +9.51% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 11:59 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | Morgan Stanley |
| WKN | MB0BQ7 |
| ISIN | DE000MB0BQ72 |
| Date issued | 09/11/2022 |
| Strike | 280 $ |
| Maturity | 20/12/2024 (174 Days) |
| Parity | 10 : 1 |
| Emission price | 5.94 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.83 € |
|---|---|
| Lowest since issue | 0.48 € |
| Spread | 0.06 € |
| Spread % | 1.34% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
312.4
USD
Average target price
316.4
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
